Literature DB >> 10454556

The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription.

P Alen1, F Claessens, G Verhoeven, W Rombauts, B Peeters.   

Abstract

Steroid receptors are conditional transcription factors that, upon binding to their response elements, regulate the expression of target genes via direct protein interactions with transcriptional coactivators. We have analyzed the functional interactions between the androgen receptor (AR) and 160-kDa nuclear receptor coactivators. Upon overexpression in mammalian cells, these coactivators enhance the transcriptional activity of both the amino-terminal domain (NTD) and the ligand-binding domain (LBD) of the AR. The coactivator activity for the LBD is strictly ligand-controlled and depends on the nature of the DNA-binding domain to which it is fused. We demonstrate that the NTD physically interacts with coactivators and with the LBD and that this interaction, like the functional interaction between the LBD and p160 coactivators, relies on the activation function 2 (AF2) core domain. The mutation of a highly conserved lysine residue in the predicted helix 3 of the LBD (K720A), however, blunts the functional interaction with coactivators but not with the NTD. Moreover, this mutation does not affect the transcriptional activity of the full-size AR. A mutation in the NTD of activation function AF1a (I182A/L183A), which dramatically impairs the activity of the AR, has no effect on the intrinsic transcriptional activity of the NTD but interferes with the cooperation between the NTD and the LBD. Finally, p160 proteins in which the three LXXLL motifs are mutated retain most of their coactivator activity for the full-size AR, although they are no longer functional for the isolated LBD. Together, these data suggest that in the native AR the efficient recruitment of coactivators requires a functional association of the NTD with the LBD and that the binding of coactivators occurs primarily through the NTD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10454556      PMCID: PMC84524          DOI: 10.1128/MCB.19.9.6085

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  72 in total

1.  AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.

Authors:  S L Anzick; J Kononen; R L Walker; D O Azorsa; M M Tanner; X Y Guan; G Sauter; O P Kallioniemi; J M Trent; P S Meltzer
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300.

Authors:  H Chen; R J Lin; R L Schiltz; D Chakravarti; A Nash; L Nagy; M L Privalsky; Y Nakatani; R M Evans
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

3.  The presence of a transcription activation function in the hormone-binding domain of androgen receptor is revealed by studies in yeast cells.

Authors:  A Moilanen; N Rouleau; T Ikonen; J J Palvimo; O A Jänne
Journal:  FEBS Lett       Date:  1997-07-28       Impact factor: 4.124

4.  Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen.

Authors:  C L Smith; Z Nawaz; B W O'Malley
Journal:  Mol Endocrinol       Date:  1997-06

5.  Steroid receptor coactivator-1 is a histone acetyltransferase.

Authors:  T E Spencer; G Jenster; M M Burcin; C D Allis; J Zhou; C A Mizzen; N J McKenna; S A Onate; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Nature       Date:  1997-09-11       Impact factor: 49.962

Review 6.  Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action.

Authors:  H Shibata; T E Spencer; S A Oñate; G Jenster; S Y Tsai; M J Tsai; B W O'Malley
Journal:  Recent Prog Horm Res       Date:  1997

7.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2.

Authors:  H Li; P J Gomes; J D Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

8.  TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors.

Authors:  J J Voegel; M J Heine; C Zechel; P Chambon; H Gronemeyer
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

9.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors.

Authors:  H Hong; K Kohli; M J Garabedian; M R Stallcup
Journal:  Mol Cell Biol       Date:  1997-05       Impact factor: 4.272

10.  Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator.

Authors:  E M McInerney; M J Tsai; B W O'Malley; B S Katzenellenbogen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

View more
  59 in total

1.  DNA recognition by the androgen receptor: evidence for an alternative DNA-dependent dimerization, and an active role of sequences flanking the response element on transactivation.

Authors:  Annemie Haelens; Guy Verrijdt; Leen Callewaert; Valerie Christiaens; Kris Schauwaers; Ben Peeters; Wilfried Rombauts; Frank Claessens
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

Review 2.  Structure and function of steroid receptor AF1 transactivation domains: induction of active conformations.

Authors:  Derek N Lavery; Iain J McEwan
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

3.  The p160 coactivator PAS-B motif stabilizes nuclear receptor binding and contributes to isoform-specific regulation by thyroid hormone receptors.

Authors:  Martin L Privalsky; Sangho Lee; Johnnie B Hahm; Briana M Young; Rebecca N G Fong; Ivan H Chan
Journal:  J Biol Chem       Date:  2009-06-01       Impact factor: 5.157

4.  Purification and identification of a novel complex which is involved in androgen receptor-dependent transcription.

Authors:  Keiko Hosohata; Peng Li; Yoshiaki Hosohata; Jun Qin; Robert G Roeder; Zhengxin Wang
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

5.  FoxO1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment.

Authors:  Qiuping Ma; Wei Fu; Pengfei Li; Santo V Nicosia; Guido Jenster; Xiaohong Zhang; Wenlong Bai
Journal:  Mol Endocrinol       Date:  2008-12-12

6.  Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Authors:  Katja Jehle; Laura Cato; Antje Neeb; Claudia Muhle-Goll; Nicole Jung; Emmanuel W Smith; Victor Buzon; Laia R Carbó; Eva Estébanez-Perpiñá; Katja Schmitz; Ljiljana Fruk; Burkhard Luy; Yu Chen; Marc B Cox; Stefan Bräse; Myles Brown; Andrew C B Cato
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

7.  NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth.

Authors:  Maria Papaioannou; Sonja Schleich; Daniela Roell; Undine Schubert; Tamzin Tanner; Frank Claessens; Rudolf Matusch; Aria Baniahmad
Journal:  Invest New Drugs       Date:  2009-09-23       Impact factor: 3.850

8.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

Review 9.  The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors.

Authors:  D P Edwards
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

10.  A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.

Authors:  Eleanor F Need; Howard I Scher; Amelia A Peters; Nicole L Moore; Albert Cheong; Charles J Ryan; Gary A Wittert; Villis R Marshall; Wayne D Tilley; Grant Buchanan
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.